For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
The purpose of this study is to find out if adding a study drug prior to surgery could prevent a pancreatic fistula after surgery in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. The study drug is a somatostatin analog, a synthetic version of a hormone made by the body—It is believed to help stop the body from making extra hormones and keep certain types of tumour cells from growing.
The purpose of this study is to compare the usual approach of patients receiving best supportive care measures alone after exhausting all available treatments to adding two study drugs to the usual approach to treat colorectal cancer. Best supportive care is defined as supportive care with drugs and other treatments that may help to make you feel better or may improve your quality of life. This study will help the study doctors find out if this different approach is better than the usual approach.
The purpose of this study is to compare the effects on you and your liver cancer of adding a drug that is used on its own to treat this disease to a two-drug combination also used to treat liver cancer, compared to the two-drug combination alone.
The purpose of this study is to compare the usual approach of chemotherapy plus radiation therapy followed by limited surgery, to using a more intense combination chemotherapy treatment followed by limited surgery.
The study approach without radiation may improve your quality of life and be equally effective at shrinking or stabilizing your cancer.
The purpose of this study is to find out if the approach of avoiding or delaying surgery in patients who have a good response to treatment with chemotherapy and radiation is as good as the usual approach for your esophageal cancer and provides better quality of life.
The purpose of this study is to compare the usual approach of continuing Somatostatin Analogues (SSA) injections during and after Peptide Receptor Radionuclide Therapy (PRRT) to stopping SSA injections when PRRT begins in patients with neuroendocrine tumours (NET).
The purpose of this study is to find out what effects adding a new drug to the standard treatment has on you and your gastroesophageal cancer compared to the standard treatment given alone.
The purpose of this study is to determine if looking at blood and images from medical scans can predict which pancreatic cysts will develop into pancreatic cancer.
Currently, researchers have not found a good way to predict which pancreatic cysts will progress into cancer, and which ones will not. Researchers are hopeful that medical images and biomarkers, or biological signals found in blood, will be able to help them make these predictions.
The purpose of this study is to test if we can determine what kind of chemotherapy to offer patients based on whether or not circulating tumour DNA (ctDNA) is found in a blood test taken after surgery for colon cancer.
Using ctDNA testing to determine what kind of chemotherapy to use is a new approach. This approach seems promising, but it is not clear if it can offer better results than standard treatment.
The purpose of this study is to compare a retreatment with Peptide Receptor Radionuclide Therapy (PRRT) to the standard treatment for your neuroendocrine cancer.
The drug being studied is a new type of drug approved for the treatment of neuroendocrine tumours (NETs). The new drug has been shown to shrink tumours in many people and seems promising, but it is not clear if receiving this drug again can offer better results than standard treatment.
